NUEVOLUTION A/S

CVR26029708

Core data

Name
NUEVOLUTION A/S
Address
Rønnegade 8 5, 2100, København Ø
Founded
May 8, 2001
Employees
101
Locations (P-units)
2View locations
Branch
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)

Keep track of NUEVOLUTION A/S

Get an email when we detect changes to financial reports, ownership or management. Save yourself checking the company again.
Free account

Description

Company and research and development activitiesNuevolution A/S is a Danish biopharmaceutical company focused on developing drug treatments for human disease within oncology, inflammatory diseases and cardiometabolic diseases.Nuevolution A/S is the inventor of Chemetics, a drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates.The Chemetics platform provides access to screening of trillions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate.Our efforts are leveraged by a proven and highly efficient drug discovery engine, and backed by a skilled and dedicated team of employees, world-class academic and corporate expert advisers catalyzing our ambition to deliver new medicines to patients.

Financials

Reporting period
2025DKK
Revenue
203,323,000
Operating profit
44,773,000
Profit before tax
40,251,000
Net income
39,754,000
Total assets
238,040,000
Equity
89,493,000
Avg. employees
80
2018–2025

Unlock financial history

Datapublica Risk Score

Locked
Assesses the risk of financial distress using the company’s accounts, history, and connections.
Company score
0 · Low100 · High

What goes into the assessment

  • Financials

  • Accounts and history

  • Owners and management

  • Company and connections

Standard: Score and risk bandPro: Also a detailed explanation of the factors

Contact

No contact details have been registered for this company.

Gazelle

Loading gazelle status…

Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.

People

Tore von Würden PetersenRoles
Board
TitlesFORMAND
Thomas FranchRoles
Management
TitlesDIREKTØR

Auditor

EY Godkendt RevisionspartnerselskabAuditorHans B. VistisenRoleState AuthorisedPublic AccountantFromJun 29, 2026
EY Godkendt RevisionspartnerselskabAuditorMads Obel KnøsgaardRoleState AuthorisedPublic AccountantFromJun 29, 2026
Amgen, Inc.🇺🇸

Foreign legal entity

Ownership100 %Voting rights100 %FromNov 15, 2023

Ultimate owners

🇺🇸Amgen, Inc.
Ownership through
Direct
100 %

Official sources